Richard Marshak, Chief Commercial Officer of TriSalus Life Sciences, Inc., filed a Form 4 on November 17, 2026, disclosing a disposition of common stock on November 16, 2026, in connection with the vesting of restricted stock units.

Key Highlights

  • Reporting person: Richard Marshak, Chief Commercial Officer of TriSalus Life Sciences, Inc. (NASDAQ:TLSI)
  • Transaction date: November 16, 2026
  • Shares disposed: 544 shares of Common Stock, coded "S" (sold), at a price of $2.43 per share
  • Purpose of sale: According to the filing, shares were sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person
  • Remaining beneficial ownership: 127,450 shares of Common Stock held directly following the transaction
  • Discretionary nature: The filing states this transaction "does not represent a discretionary sale by the Reporting Person"

Marshak's RSU Vesting and Tax Withholding Sale at TriSalus Life Sciences

According to the Form 4 filed with the SEC on November 17, 2026, Richard Marshak, serving as Chief Commercial Officer of TriSalus Life Sciences, Inc. (NASDAQ:TLSI), disposed of 544 shares of Common Stock on November 16, 2026, at a price of $2.43 per share. The transaction was assigned code "S" in Table I of the filing, indicating a sale of non-derivative securities.

The filing's footnote clarifies that the shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units previously awarded to Marshak. The filing states that this transaction "does not represent a discretionary sale by the Reporting Person." No derivative securities transactions were reported in Table II of the filing.

Following the reported transaction, Marshak held 127,450 shares of Common Stock directly, according to the filing. The Form 4 was signed by Mary Szela as Attorney-in-Fact on November 17, 2026. No amendment date was listed, indicating this is an original filing and not a revision of a prior submission.

What Was Disclosed

TriSalus Life Sciences Chief Commercial Officer Richard Marshak filed a Form 4 reporting the disposal of 544 shares of Common Stock at $2.43 on November 16, 2026, to satisfy tax withholding on vested restricted stock units, leaving him with 127,450 shares directly held.